Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix and Iconix to Co-develop Drug Toxicology Research Tools

NEW YORK, Feb. 7 (GenomeWeb News) - Affymetrix and Iconix Pharmaceuticals plan to co-develop products to help study the toxicological and pharmacological properties of drugs and drug candidates, the firms said today.

 

Under the terms of the agreement, Affymetrix will combine its GeneChip platform with Iconix's DrugMatrix 640 compound reference database and analysis software. Researchers will also be able to compare gene-expression profiles to Iconix's Drug Signatures library to help predict the impact that gene-expression changes may have on the body's toxic response, the companies said.

 

Financial terms were not disclosed.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.